The New Funding Model Collaboration among partners
2 Content 1 Introducing the new funding model & the transition 2 Preparations for the full roll-out to standard applicants
3 Principles of the new funding model Greater alignment with country schedules, context, and priorities Principles of the new funding model Focus on countries with the highest disease burden and lowest ability to pay, while keeping the portfolio global Simplicity for both implementers and the Global Fund Predictability of process and financing levels Ability to elicit full expressions of demand and reward ambition
4 Overview of the new funding model NSP support Determination of split between diseases & HCSS TRP review Grant Approval Committee Unfunded quality demand Board approval NSP Country dialogue Concept Note Determine / approve adjusted funding amount Grant-making with dialogue Indicative funding Band allocation Incentive funding Allocation formula Potential for technical TB support throughout the process: strategy to detailed grant description
Overview on early applicant and interim countries selected for the transition period 5 Early applicant Interim applicant 7 6 20 Eastern Europe and Central Asia Latin America and the Caribbean Asia-Pacific HIV 28 Malaria 19 TB Eurasian Harm Reduction Network, Russia, Moldova, Albania, Kosovo El Salvador, Jamaica Myanmar, Philippines, India, Thailand, Nepal, Mongolia, Multicountry Western Pacific Regional Elimination Initiative in Mesoamerica and Hispaniola, Suriname Myanmar, Regional Artemisinin Resistance Initiative, Indonesia Kazakhstan, Belarus 23 Nicaragua, Dominican Republic Myanmar, Philippines, Cambodia, Viet Nam, Bangladesh, Solomon Islands, Indonesia, Pakistan, PNG, Sri Lanka 11 Francophone Africa DRC, Cameroon, Niger, Togo Chad, DRC, Niger, Côte d'ivoire, Burundi, Rwanda Benin 26 Africa and Middle East Zimbabwe, Kenya, Lesotho, Ghana, Malawi, South Africa, Nigeria, Uganda, Tanzania, Mozambique Yemen, Malawi, Mozambique, Nigeria Swaziland, Zambia, Tanzania, Sudan Zimbabwe, Ethiopia, Kenya, Mozambique, South Africa, Tanzania, Zambia, Egypt For early applicants, this is the 2014-2016 amount. For interim applicants, this covers the allocation from the $1.9B.
Update on early applicants 6 Design Work to date reveals necessity for partners in grant-making Concept note revision to conclude shortly for mid-june release to applicants TRP meeting in October or November can allow timing for December board Accelerated early applicants Early applicants The grants for El Salvador, Myanmar and Zimbabwe were presented to the Grants Approval Committee on 3 rd June Seeking board approval in June DRC working with partners to clarify data for disease burden and to set priorities Kazakhstan progressing with country dialogue towards policy reform. Next meeting 17-19 June. Philippines seek TRP early engagement in July, for CN submission in September. Next meeting 17-21 June with country team for concept note development launch Regional applicants Meso-America (malaria) working towards regional strategy meeting in Costa Rica, 24-27 June Artemisinin resistance response appointing PR and RCM in June, next meeting in Cambodia, 15-17 July with country team and TB experts Eurasian HIV network seeks TRP early feedback this month for August CN. Meeting in Vilnius this week on regional dialogue. Next meeting 17-21 July on CN development.
Interim applicant progress (I/II) 47 country-disease components already agreed to GAC timeline over 2013/2014 2013 2014 7 Interim applicants (disease program) Pakistan (TB) Papua New Guinea (TB) Kenya (TB) Chad (Malaria) Mozambique (Malaria) Bangladesh (TB) India (HIV) Indonesia (Malaria) Jamaica (HIV) Russian Federation (HIV) Sudan (Malaria) Zimbabwe (TB) Belarus (TB) Indonesia (TB) Mozambique (HIV)* Nigeria (Malaria)* Tanzania (Malaria) Côte d'ivoire (Malaria)* Philippines (HIV) Solomon Islands (TB) Zambia (Malaria & TB) Nigeria (HIV)* South Africa (HIV& TB)* Niger (HIV) Ghana (HIV)* Tanzania (HIV)* DRC (Malaria)* Malawi (HIV)* Sri Lanka (TB) Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Dec. Timing for materials submission Materials to Secretariat 1.5 to 2 months in advance Materials to Secretariat at least 8 days in advance GAC usually scheduled in 3rd or 4th week of each month Current information on timing available at http://www.theglobalfund.org /en/activities/renewals/ Light process Consultative approach Renewals *Countries will be reviewed by TRP Time when countries expect to access funds GAC meeting TRP review
Interim applicant progress (II/II) Twelve country-disease components yet to provide preliminary GAC dates 8 2013 2014 Interim applicants (disease program) Dominican Republic (TB) Mongolia (HIV) Togo (HIV) Viet Nam (TB) Yemen (Malaria) Tanzania (TB) Multi-country W Pacific (HIV) Burundi (Malaria) Rwanda (Malaria) Kenya (HIV) Nepal (HIV) Ethiopia (TB) Mozambique (TB)* Lesotho (HIV)* Thailand (HIV) Cameroon (HIV) Albania (HIV) Benin (TB) Cambodia (TB) Egypt (TB) Kosovo (HIV) Malawi (Malaria) Moldova (HIV) Nicaragua (TB) Suriname (Malaria) Swaziland (Malaria) Niger (Malaria)* Uganda (HIV)* Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Dec. Exact GAC month to be confirmed Light process Consultative approach Renewals *Countries will be reviewed by TRP Time when countries expect to access funds GAC meeting TRP review
9 Content 1 Introducing the new funding model & the transition 2 Preparations for the full roll-out
2 Preparing for the full roll-out Key focus areas 10 Strengthen NSPs Facilitate review of country program reviews and National Strategic Plan (NSP) Work with partners to prioritize countries for NSP support A Improve data Review country disease burden data used in allocation B Work with partners to strengthen epidemiological information, especially at regional level and for KAPs C Ensure capacity for full roll-out Map and align technical support for early 2014 applicants Adapt Secretariat resourcing levels to handle surge Develop and roll-out training for CTs, partners and countries D Involve key constituencies Target CCM funding to strengthen Key Affected Populations (KAPs) and civil society engagement in CCMs (pilot in 2013) Work with TA funders / providers to strengthen KAP and civil society capacity
2 Preparing for the full roll-out Request to technical partners 11 Work with partners to prioritize countries for NSP support A Which countries are you prioritizing? Which countries have been identified as requiring TA but you do not have the capacity to support them? Review country disease burden data used in allocation B Official data from technical partners is the sole source of data used for allocation and eligibility purposes. Global Fund will send broad communication to technical partners on data needs for the NFM. Work with partners to strengthen epidemiological information, especially at regional level and for KAPs C Let us know where there are epidemiological gaps in the portfolio. How to we move forward on these? Map and align technical support for early 2014 applicants D We will provide a preliminary list by July. Do you have a list of countries you expect to come in early 2014?